Latest Oncology News

Roundtable Discussion: Participants Analyze Different Classes of Drugs for Second-line Multiple Myeloma

August 04, 2021

Two years after being diagnosed with multiple myeloma and treated with the Dara-Rd regimen as induction therapy, a 78-year-old patient presented with mild fatigue during routine follow-up. James E. Hoffman, MD, discussed the case with a group of peers.

Clinical Potential of onCARlytics Under Exploration in Solid Tumors

August 04, 2021

Research in the solid tumors arena around the combination of the oncolytic virus technology CF33-CD19 and the CD19-targeting CAR placental-derived T-cell therapy CyCART-19, is underway to explore it’s potential in this patient population.

Exploration of WEE-1 Inhibition in Recurrent/Persistent Uterine Serous Carcinoma Continues to Phase 2

August 04, 2021

Following the success of a phase 1 study that showed its potential for accelerated FDA approval in the future, the WEE-1 inhibitor, ZN-c3 has been dosed for the first time in the newly launched phase 2 study, which is exploring the agent for the treatment of adult women with recurrent or persistent uterine serous carcinoma.

Plinabulin Plus Docetaxel Combination Succeeds in Improving OS in NSCLC With EGFR Wild Type

August 04, 2021

The combination of plinabulin with docetaxel showed improvement in overall survival compared with docetaxel alone as treatment of patients with second- and third-line non –small cell lung cancer with EGFR wild type, meeting the primary end point of the phase 3 DUBLIN-3 clinical trial.

Low-Dose Chemotherapy With Immunotherapy Shows Efficacy in UC

August 03, 2021

In an interview with Targeted Oncology™, Rhonda L. Bitting, MD, discussed the efficacy results and key takeaways of a study investigating low-dose paclitaxel plus pembrolizumab in patients with platinum-refractory UC. 

BMS Pulls Romidepsin’s Peripheral T-cell Lymphoma from US Market

August 03, 2021

Bristol Myers Squibb has decided to withdraw the approval for romidepsin, a histone deacetylase inhibitor, for the treatment of adults with peripheral T-cell lymphoma who received at least 1 prior therapy after a confirmatory phase 3 study missed its primary end point.